Tides Medical will be exhibiting October 7-9, 2016 at the Fall Symposium on Advanced Wound Care (SAWC) in Las Vegas, NV. The company will be showcasing Artacent Wound®, Tides Medical’s newly released dual-layer amniotic patch that was specifically designed as a wound covering.
Artacent Wound® received preliminary approval for a Level II HCPCS Q-code in May 2016. The new code is expected to go in to effect beginning in January 2017. Tides Medical is currently enrolling 125 patients in a multi-center randomized controlled trial (RCT) comparing Artacent Wound® with current standard of care methods for the treatment of diabetic and vascular lower extremity wounds. The study will be the most robust RCT to date investigating the healing effects of amniotic tissue on chronic wounds.
About Tides Medical
Tides Medical, a privately funded medical technology firm located in Lafayette, LA, is a leader in birth tissue technology. The company’s focus is on providing patients with safe, effective therapies, on supplying physicians with reliable products and service, and on supporting distributors and hospitals with reliable inventory and personalized attention. Contact Tides Medical today for more information about the most advanced products in regenerative medicine.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161005006472/en/Business Wire
Last updated on: 05/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.